This promotional website has been developed, organised and funded by Boehringer Ingelheim.
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters
How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters
Diabetes Distress in adults with type 2 diabetes: Summary
How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?
How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?
The impact of clinical inertia on the achievement of treatment targets in adults with type 2 diabetes: Summary
How and when to switch or add in medications in adult type 2 diabetes
Switching and adding in medications in adult type 2 diabetes
A pharmacist’s guide to switching and adding in medications in adult type 2 diabetes
Hypoglycaemia in adult type 2 diabetes
Managing hypoglycaemia in type 2 diabetes
Hypoglycaemia: Insights from a primary care and patient perspective
Managing type 2 diabetes in primary care
Managing type 2 diabetes in primary care
Convenience of Trajenta (linagliptin) 5 mg once daily in a broad range of people with type 2 diabetes
Management of type 2 diabetes in the elderly and frail
Actively support your adult patients with type 2 diabetes during Ramadan
Supporting your patients during Ramadan
The risks of fasting during Ramadan in adults with type 2 diabetes
Ramadan fasting: A guide for adults with type 2 diabetes
The event starts in:
Coming soon
Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.
PC-GB-107170 V7 | February 2024
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2023 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
This content is for healthcare professionals in Great Britain and Northern Ireland only.